Astrantus’s Haemonetics HAE Stock Holding History

Astrantus’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,800	Closed	-$202K	–	226
2021 Q4	$202K	Buy	+3,800	New	+$232K	0.15%	208

Other funds holding HAE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $17.5B AUM 29.92% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

Astrantus's HAE Position: Q1 2022 in Review

Astrantus sold out of Haemonetics (HAE) in Q1 2022, closing a stake of 3,800 shares — an estimated $202K sold.

Astrantus first reported a position in HAE in Q4 2021 and held it in 1 quarter. The position peaked at $202K in Q4 2021. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.

Astrantus reported no remaining Haemonetics position as of Q1 2022 after selling out during the quarter.
Astrantus sold 3,800 Haemonetics shares in Q1 2022, an estimated $202K.
Astrantus first reported a position in Haemonetics in Q4 2021 and held it in 1 quarter.
Astrantus's Haemonetics position peaked at $202K in Q4 2021.
242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.